2014

1. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

   The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206

2. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

   Blood, Vol. 123, Núm. 26, pp. 4136-4142